Kiniksa Pharmaceuticals International, plc (NasdaqGS: KNSA)
Health Care · Biotechnology · GB
$80.31
+0.66% today · +109.3% 1Y
Kiniksa Pharmaceuticals International, plc (NasdaqGS: KNSA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.22B and employs 366 people.
Over the last twelve months the share price has gained 109.3%, trading between 35.20 and 82.94.
Tweenvest scores Kiniksa Pharmaceuticals International, plc across four factors: quality 67/100, value 23/100. Its strongest factor is quality.
KNSA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.22B
- Revenue (TTM)
- $840.85M
- P/E
- 80.56
- EPS
- 0.99
- Dividend yield
- —
- Beta (5Y)
- 0.04
- 52-week high
- $82.94
- 52-week low
- $35.20
- Avg volume (3M)
- —
- Shares outstanding
- 78.02M
- Employees
- 366
- Next earnings
- —
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- ISIN
- GB00BRXB0C07
- Founded
- 2015
- Listed since
- May 24, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Immunovant, Inc.NasdaqGS: IMVT | $6.29B | $29.81 | -2.17% |
| GRAIL, Inc.NasdaqGS: GRAL | $6.28B | $136.62 | -2.82% |
| Kodiak Sciences Inc.NasdaqGM: KOD | $6.26B | $98.84 | -1.03% |
| Rhythm Pharmaceuticals, Inc.NasdaqGM: RYTM | $6.25B | $90.26 | -0.58% |
| Biocon LimitedNSEI: BIOCON | $5.88B | Rs349.40 | -5.75% |
| CG Oncology, Inc.NasdaqGS: CGON | $5.66B | $63.58 | -0.38% |
| Erasca, Inc.NasdaqGS: ERAS | $5.61B | $15.63 | -2.53% |
| Mirum Pharmaceuticals, Inc.NasdaqGM: MIRM | $5.58B | $86.83 | +0.95% |
Figures last refreshed Oct 11, 2026.